UMeWorld Debuts 'UMEW' Ticker in Strategic Shift to Delaware

MIAMI, FL – January 21, 2026 – UMeWorld Inc. began a new chapter on the public markets today, as its common stock started trading under the new ticker symbol “UMEW” on the OTC Markets. The change marks the culmination of a significant corporate overhaul designed to anchor the company firmly within the United States legal and financial framework, a move that signals ambitions far beyond a simple administrative update.

The new trading symbol follows a FINRA-approved corporate action that included the company's redomiciliation from the British Virgin Islands to the State of Delaware, a formal name change from UMeWorld Limited to UMeWorld Inc., and the assignment of a new CUSIP number (90292A105). These actions are the final public-facing steps of a process that began with a share exchange and domestication transaction on October 2, 2025, which established the Delaware-based UMeWorld Inc. as the successor public entity.

While the ticker change provides a fresh identity, the underlying strategic shift to a U.S. domicile speaks volumes about the company's future direction, aiming to enhance governance, transparency, and appeal to a broader base of American investors.

A Strategic Pivot from Offshore to Onshore

The decision to relocate its corporate home from the British Virgin Islands (BVI), a popular offshore financial center, to Delaware is a calculated and increasingly common maneuver for international companies seeking to bolster their standing in the U.S. market. Delaware is widely regarded as the gold standard for corporate incorporation in the United States, primarily due to its highly developed and predictable body of corporate law, the Delaware General Corporation Law (DGCL).

This legal framework, interpreted by the state's specialized Court of Chancery, provides a stable and expert environment for resolving corporate disputes, a feature highly valued by investors and management teams alike. For a company trading on the OTC Markets, moving from an offshore jurisdiction to Delaware is often interpreted as a significant step toward greater corporate transparency and accountability. It aligns the company with the robust governance standards expected by U.S. institutional and retail investors, potentially easing concerns about regulatory oversight.

This redomiciliation is a core component of UMeWorld's “Strategy 2026,” an initiative aimed at strengthening its capital markets infrastructure. By establishing itself as a domestic U.S. corporation, the company is positioning itself for its next major ambition: a potential uplisting to a national exchange such as the NYSE American or Nasdaq. Such a move would dramatically increase its visibility, enhance trading liquidity, and open the door to a wider pool of institutional capital, which is often restricted from investing in foreign-domiciled or OTC-listed entities.

Beyond the Ticker: A Dual-Focus Biotech Innovator

The press release announcing the ticker change offered little detail on UMeWorld's core business, but the company, founded in 1997 and now based in Miami, has evolved significantly from its original focus on educational technology in China. Today, UMeWorld operates a sophisticated dual-vertical business model powered by a proprietary enzymatic biotechnology platform.

One arm of the company is dedicated to functional nutrition. Under its DAGola® brand, UMeWorld develops and sells diacylglycerol-based cooking oils. These products are not just pantry staples; they are marketed as functional foods with clinically demonstrated health benefits, including the ability to help reduce triglycerides and uric acid, supporting overall metabolic health. The company has secured distribution in the U.S. through major online retailers like Amazon and Walmart, and also maintains a market presence in China. Looking to expand its high-margin opportunities, UMeWorld is also pursuing a B2B strategy to supply its clinically validated DAG oils as an ingredient to other food manufacturers.

The second vertical targets the rapidly growing renewable energy sector. Through its Verdant Biofuel platform, UMeWorld is focused on converting waste oils and abundant vegetable waste into high-value biofuels, with a particular emphasis on Sustainable Aviation Fuel (SAF). The demand for SAF is surging globally, driven by regulatory mandates in the European Union and the United States aimed at decarbonizing the aviation industry. UMeWorld is actively developing a 10,000-tonne annual capacity enzymatic biofuel facility in Malaysia, strategically located to process local waste-based feedstocks and engineered to meet the stringent carbon-intensity requirements of regulations like the EU’s ReFuelEU Aviation initiative.

This dual focus on health and sustainability is unified by the company's core enzymatic biotechnology, which it claims provides critical advantages, including feedstock flexibility, lower carbon production processes, and greater capital efficiency.

The Road Ahead: Growth Ambitions and Financial Realities

UMeWorld's strategic restructuring comes at a pivotal moment. The company's leadership has laid out an aggressive growth plan, but it is not without its challenges. According to its most recent Form 20-F filing for the fiscal year ending September 30, 2025, the company reported an increased net loss and noted that there was “substantial doubt about the company's ability to continue as a going concern without additional funding.”

This disclosure highlights the critical importance of its strategic pivot. The move to Delaware and the pursuit of an exchange uplisting are not just for appearances; they are essential steps in a plan to attract the necessary capital to fund its ambitious projects. The company must balance its operational expansion with the financial realities of a pre-profitability growth company.

Despite the financial pressures, there are positive indicators. Revenue from the DAGola cooking oil business more than doubled in fiscal year 2025, albeit from a modest base. Furthermore, the company has released ambitious forward-looking revenue projections, estimating $5 million for 2024 and over $10 million by the end of 2025, partly driven by an anticipated acquisition of a Miami-based retailer. In the longer term, a planned palm oil production operation is projected to have the potential to generate over $100 million in revenue within 18 months of becoming operational.

This combination of high-growth potential and significant financial risk is characteristic of emerging biotech and cleantech companies. The successful completion of the FINRA-approved corporate action and the establishment of the new 'UMEW' trading identity provide a clearer, more streamlined structure for investors to evaluate this complex and evolving story. For UMeWorld, the formal debut as a Delaware corporation on the U.S. market is the starting line for a new and demanding race toward growth and profitability.